Inhibition of stathmin1 accelerates the metastatic process

Cancer Research

Volumn 72, Issue 20, 2012, Pages 5407-5417

  Williams, Karin ^a   Ghosh, Ritwik ^b   Giridhar, Premkumar Vummidi ^a   Gu, Guangyu ^c   Case, Thomas ^b   Belcher, Scott M ^a   Kasper, Susan ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ARUP LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN STMN1; STATHMIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CANCER STAGING; CELL ADHESION; CELL MIGRATION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; METASTASIS POTENTIAL; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE HYPERTROPHY; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; UNDIFFERENTIATED CARCINOMA;

BASE SEQUENCE; CELLS, CULTURED; DNA PRIMERS; DOWN-REGULATION; HUMANS; MALE; NEOPLASM METASTASIS; SIGNAL TRANSDUCTION; STATHMIN;

EID: 84867500471     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-1158     Document Type: Article

References (41)

1. Ghosh R, Gu G, Tillman E, Yuan J, Wang Y, Fazli L, et al. Increased expression and differential phosphorylation of stathmin may promote prostate cancer progression. Prostate 2007;67:1038-52.
2. DeAngelis JT, Li Y, Mitchell N, Wilson L, Kim H, Tollefsbol TO. 2D difference gel electrophoresis analysis of different time points during the course of neoplastic transformation of human mammary epithelial cells. J Proteome Res 2011;10:447-58.
3. Ogino S, Nosho K, Baba Y, Kure S, Shima K, Irahara N, et al. A cohort study of STMN1 expression in colorectal cancer: body mass index and prognosis. Am J Gastroenterol 2009;104:2047-56.
4. Björklund P, Cupisti K, Fryknäs M, Isaksson A, Willenberg HS, Akerström G, et al. Stathmin as a marker for malignancy in pheochromocytomas. Exp Clin Endocrinol Diabetes 2010;118:27-30.
5. Ge F, Xiao CL, Bi LJ, Tao SC, Xiong S, Yin XF, et al. Quantitative phosphoproteomics of proteasome inhibition in multiple myeloma cells. PLoS ONE 2010;5:e13095.
6. Hsieh SY, Huang SF, Yu MC, Yeh TS, Chen TC, Lin YJ, et al. Stathmin1 overexpression associated with polyploidy, tumor-cell invasion, early recurrence, and poor prognosis in human hepatoma. Mol Carcinog 2010;49:476-87.
7. Mistry SJ, Atweh GF. Role of stathmin in the regulation of the mitotic spindle: potential applications in cancer therapy. Mt Sinai J Med 2002;69:299-304. (Pubitemid 35244131)
8. Steinmetz MO. Structure and thermodynamics of the tubulin-stathmin interaction. J Struct Biol 2007;158:137-47. (Pubitemid 46719987)
9. Charbaut E, Curmi PA, Ozon S, Lachkar S, Redeker V, Sobel A. Stathmin family proteins display specific molecular and tubulin binding properties. J Biol Chem 2001;276:16146-54.
10. Iancu C, Mistry SJ, Arkin S, Wallenstein S, Atweh GF. Effects of stathmin inhibition on the mitotic spindle. J Cell Sci 2001;114:909-16. (Pubitemid 32266262)
11. Gadea BB, Ruderman JV. Aurora B is required for mitotic chromatin-induced phosphorylation of Op18/stathmin. Proc Natl Acad Sci U S A 2006;103:4493-8.
12. Ringhoff DN, Cassimeris L. Stathmin regulates centrosomal nucleation of microtubules and tubulin dimer/polymer partitioning. Mol Biol Cell 2009;20:3451-8.
13. Horwitz SB, Shen HJ, He L, Dittmar P, Neef R, Chen J, et al. The microtubule-destabilizing activity of metablastin (p19) is controlled by phosphorylation. J Biol Chem 1997;272:8129-32. (Pubitemid 27147759)
14. Cassimeris L. The oncoprotein 18/stathmin family of microtubule destabilizers. Curr Opin Cell Biol 2002;14:18-24. (Pubitemid 34131652)
15. Niethammer P, Bastiaens P, Karsenti E. Stathmin-tubulin interaction gradients in motile and mitotic cells. Science 2004;303:1862-6. (Pubitemid 38374877)
16. Zarubin T, Han J. Activation and signaling of the p38 MAP kinase pathway. Cell Res 2005;15:11-8. (Pubitemid 41653958)
17. Mizumura K, Takeda K, Hashimoto S, Horie T, Ichijo H. Identification of Op18/stathmin as a potential target of ASK1-p38 MAP kinase cascade. J Cell Physiol 2006;206:363-70. (Pubitemid 43062804)
18. Betapudi V, Licate LS, Egelhoff TT. Distinct roles of nonmuscle myosin II isoforms in the regulation of MDA-MB-231 breast cancer cell spreading and migration. Cancer Res 2006;66:4725-33.
19. Li N, Jiang P, Du W, Wu Z, Li C, Qiao M, et al. Siva1 suppresses epithelial-mesenchymal transition and metastasis of tumor cells by inhibiting stathmin and stabilizing microtubules. Proc Natl Acad Sci U S A 2011;108:12851-6.
20. Brown KA, Aakre ME, Gorska AE, Price JO, Eltom SE, Pietenpol JA, et al. Induction by transforming growth factor-beta1 of epithelial to mesenchymal transition is a rare event in vitro. Breast Cancer Res 2004;6:R215-31.
21. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009;139:871-90.
22. Zohn IE, Li Y, Skolnik EY, Anderson KV, Han J, Niswander L. p38 and a p38-interacting protein are critical for downregulation of E-cadherin during mouse gastrulation. Cell 2006;125:957-69. (Pubitemid 43810156)
23. Gu G, Yuan J, Wills M, Kasper S. Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res 2007;67:4807-15. (Pubitemid 46910189)
24. Pitkänen-Arsiola T, Tillman JE, Gu G, Yuan J, Roberts RL, Wantroba M, et al. Androgen and anti-androgen treatment modulates androgen receptor activity and DJ-1 stability. Prostate 2006;66:1177-93. (Pubitemid 44175340)
25. Tillman JE, Yuan J, Gu G, Fazli L, Ghosh R, Flynt AS, et al. DJ-1 binds androgen receptor directly and mediates its activity in hormonally treated prostate cancer cells. Cancer Res 2007;67:4630-7. (Pubitemid 46910167)
26. Chen HC. Boyden chamber assay. Methods Mol Biol 2005;294:15-22.
27. Kleinman HK, Jacob K. Invasion assays. Curr Protoc Cell Biol 2001;Chapter 12:Unit 12.12.
28. Willott E, Balda MS, Fanning AS, Jameson B, Van Itallie C, Anderson JM. The tight junction protein ZO-1 is homologous to the Drosophila discs-large tumor suppressor protein of septate junctions. Proc Natl Acad Sci U S A 1993;90:7834-8. (Pubitemid 23250045)
29. Hartsock A, Nelson WJ. Adherens and tight junctions: structure, function and connections to the actin cytoskeleton. Biochim Biophys Acta 2008;1778:660-9.
30. Hu JY, Chu ZG, Han J, Dang YM, Yan H, Zhang Q, et al. The p38/MAPK pathway regulates microtubule polymerization through phosphorylation of MAP4 and Op18 in hypoxic cells. Cell Mol Life Sci 2010;67:321-33.
31. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010;141:52-67.
32. Kim ES, Kim MS, Moon A. TGF-beta-induced upregulation of MMP-2 and MMP-9 depends on p38 MAPK, but not ERK signaling in MCF10A human breast epithelial cells. Int J Oncol 2004;25:1375-82.
33. Miettinen PJ, Ebner R, Lopez AR, Derynck R. TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors. J Cell Biol 1994;127:2021-36.
34. Yu L, Hebert MC, Zhang YE. TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses. EMBO J 2002;21:3749-59. (Pubitemid 34787048)
35. Lopez-Otin C, Matrisian LM. Emerging roles of proteases in tumour suppression. Nat Rev Cancer 2007;7:800-8. (Pubitemid 47463671)
36. Scorilas A, Karameris A, Arnogiannaki N, Ardavanis A, Bassilopoulos P, Trangas T, et al. Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients. Br J Cancer 2001;84:1488-96. (Pubitemid 32579341)
37. Takeha S, Fujiyama Y, Bamba T, Sorsa T, Nagura H, Ohtani H. Stromal expression of MMP-9 and urokinase receptor is inversely associated with liver metastasis and with infiltrating growth in human colorectal cancer: a novel approach from immune/inflammatory aspect. Jpn J Cancer Res 1997;88:72-81. (Pubitemid 27096232)
38. Miller GJ, Torkko KC. Natural history of prostate cancer-epidemiologic considerations. Epidemiol Rev 2001;23:14-8. (Pubitemid 32906608)
39. Gleason D. The Veteran's Administration Cooperative Urologic Research Group: histologic grading and clinical staging of prostatic carcinoma. Philadelphia: Lea and Febiger; 1977. p. 171-98
40. Ledford H. Cancer theory faces doubts. Nature 2011;472:273.
41. Savagner P. The epithelial-mesenchymal transition (EMT) phenomenon. Ann Oncol 2011;21(Suppl 7):vii89-92.